Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Keybanc Maintains Overweight on Target, Lowers Price Target to $180

Keybanc analyst Bradley Thomas maintains Target (NYSE:TGT) with a Overweight and lowers the price target from $200 to $180.
byBenzinga Newsdesk
November 17, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Keybanc analyst Bradley Thomas maintains Target (NYSE:TGT) with a Overweight and lowers the price target from $200 to $180.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Cardiol Therapeutics Presented Topline Data From Its Phase II MAvERIC-Pilot Study Investigating CardiolRx For Recurrent Pericarditis; Administration Of CardiolRx Led To A Marked Reduction In The Primary Efficacy Endpoint Of Pericarditis Pain

By Benzinga Newsdesk
June 13, 8:01 AM
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce inflammation in patients with elevated CRP89% of patients have

CRDL